| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | XAGE1A |
| Uniprot No | Q9HD64 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-81aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMESPKKK NQQLKVGILH LGSRQKKIRI QLRSQCATWK VICKSCISQT PGINLDLGSG VKVKIIPKEE HCKMPEAGEE QPQV |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于XAGE1A重组蛋白的模拟参考文献示例(内容为模拟生成，建议通过学术数据库检索真实文献)：
---
1. **文献名称**: *Expression and Purification of Recombinant XAGE1A Protein for Cancer Immunotherapy*
**作者**: Zhang L, et al.
**摘要**: 研究报道了XAGE1A重组蛋白在大肠杆菌中的高效表达与纯化工艺，并验证其免疫反应性，为基于XAGE1A的肿瘤疫苗开发提供基础。
2. **文献名称**: *XAGE1A as a Novel Cancer/Testis Antigen: Immunogenicity Analysis in Non-Small Cell Lung Cancer*
**作者**: Tanaka K, et al.
**摘要**: 通过重组XAGE1A蛋白刺激患者外周血单核细胞，证实其在非小细胞肺癌中可诱导特异性T细胞应答，提示其作为免疫治疗靶点的潜力。
3. **文献名称**: *Proteomic Identification of XAGE1A Autoantibodies in Prostate Cancer Sera*
**作者**: Müller R, et al.
**摘要**: 利用重组XAGE1A蛋白进行血清学筛选，发现前列腺癌患者中特异性抗体的存在，支持其作为诊断生物标志物的可能性。
4. **文献名称**: *Structural and Functional Characterization of XAGE1A Recombinant Protein in Tumor Progression*
**作者**: Chen H, et al.
**摘要**: 解析了重组XAGE1A蛋白的晶体结构，并发现其通过调控EGFR信号通路促进肿瘤细胞迁移，为靶向治疗提供新方向。
---
**提示**：以上内容为模拟生成，实际文献请通过PubMed、Web of Science或Google Scholar检索关键词(如"XAGE1A recombinant protein" + "cancer")。
XAGE1A (X antigen family member 1A) is a cancer-testis antigen (CTA) encoded by the XAGE gene cluster located on chromosome Xq28. Initially identified in studies of lung and prostate cancers, XAGE1A is predominantly expressed in germ cells under normal physiological conditions but becomes aberrantly overexpressed in various malignancies. This restricted expression pattern makes it a promising target for cancer immunotherapy and diagnostic biomarker development.
The XAGE1A protein consists of 145 amino acids with a conserved PAGE/GAGE-like domain, which is characteristic of CTAs involved in protein-protein interactions and intracellular signaling. Its recombinant form is typically produced using prokaryotic (e.g., E. coli) or eukaryotic expression systems to preserve post-translational modifications critical for immunological studies. Recombinant XAGE1A maintains antigenic epitopes that enable its application in serological tests, T-cell response assays, and antibody production.
Functionally, XAGE1A has been implicated in tumor progression through mechanisms involving cell cycle regulation, apoptosis resistance, and immune evasion. Its overexpression correlates with advanced disease stages in lung adenocarcinoma, prostate cancer, and Ewing sarcoma. Notably, XAGE1A-specific antibodies and cytotoxic T lymphocytes have been detected in cancer patients, highlighting its immunogenic potential.
Current research focuses on leveraging recombinant XAGE1A for diagnostic tools (e.g., ELISA-based detection of autoantibodies) and therapeutic vaccines. Challenges include addressing its heterogeneous expression across tumors and developing strategies to enhance immune recognition. Emerging studies also explore its role in cancer stem cell maintenance and epithelial-mesenchymal transition, expanding its potential applications in precision oncology.
×
